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Abstract
The considerable uncertainty regarding cancer risks associated with inherited mutations of BRCA2 is due to unknown
factors. To investigate whether common genetic variants modify penetrance for BRCA2 mutation carriers, we undertook a
two-staged genome-wide association study in BRCA2 mutation carriers. In stage 1 using the Affymetrix 6.0 platform, 592,163
filtered SNPs genotyped were available on 899 young (,40 years) affected and 804 unaffected carriers of European
ancestry. Associations were evaluated using a survival-based score test adjusted for familial correlations and stratified by
country of the study and BRCA2*6174delT mutation status. The genomic inflation factor (l) was 1.011. The stage 1
association analysis revealed multiple variants associated with breast cancer risk: 3 SNPs had p-values,10
25 and 39 SNPs
had p-values,10
24. These variants included several previously associated with sporadic breast cancer risk and two novel
loci on chromosome 20 (rs311499) and chromosome 10 (rs16917302). The chromosome 10 locus was in ZNF365, which
contains another variant that has recently been associated with breast cancer in an independent study of unselected cases.
In stage 2, the top 85 loci from stage 1 were genotyped in 1,264 cases and 1,222 controls. Hazard ratios (HR) and 95%
confidence intervals (CI) for stage 1 and 2 were combined and estimated using a retrospective likelihood approach,
stratified by country of residence and the most common mutation, BRCA2*6174delT. The combined per allele HR of the
minor allele for the novel loci rs16917302 was 0.75 (95% CI 0.66–0.86, p~3:8|10{5) and for rs311499 was 0.72 (95% CI
0.61–0.85, p~6:6|10{5). FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR=1.28, 95%
CI 1.18–1.39, p~1:2|10{8). These results indicate that SNPs that modify BRCA2 penetrance identified by an agnostic
approach thus far are limited to variants that also modify risk of sporadic BRCA2 wild-type breast cancer.
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After more than a decade of clinical testing for mutations of
BRCA1 and BRCA2, there remains considerable uncertainty
regarding cancer risks associated with inherited mutations of these
genes. This variable penetrance is most striking for BRCA2 [1–4],
and it affects medical management [5]. Women with the same
BRCA2 mutation may develop breast, ovarian or other cancers at
different ages or not at all [6]. In a segregation analysis of families
identified through breast cancer cases diagnosed before age 55, the
residual familial clustering after accounting for BRCA1 and BRCA2
mutations could be explained by a large number of low penetrance
genes with multiplicative effects on breast cancer risk [7,8]. A
candidate gene approach in BRCA2 mutation carriers led to the
discovery of loci that modify the penetrance of BRCA2 mutations,
such as RAD51 135 G.C [9] and perhaps CASP8 [10,11] and
IGFBP2 [12], if replicated. To investigate whether other common
single nucleotide polymorphisms (SNP), copy number variants
(CNV), or copy number polymorphisms (CNP) modify penetrance
for BRCA2 mutation carriers, we undertook a two-staged genome-
wide association study (GWAS) in BRCA2 mutation carriers from
the international Consortium for Investigators of Modifiers of
BRCA1/2 (CIMBA) and other international studies. We hypoth-
esized that an agnostic search for breast cancer loci in an enriched
population of BRCA2 mutation carriers, the first among this high
risk population, would provide greater power than a sporadic
population of equal number, and would yield associations specific
to BRCA2 carriers and/or the general population.
Results
Stage 1 and Stage 2 Genotyping
In stage 1, genotype data were available for 899 young (,40
years) affected and 804 older (.40 years) unaffected carriers of
European ancestry after quality control filtering and removal of
ethnic outliers (Figure S1). A total of 592,163 filtered SNPs
genotyped using the Affymetrix Genome-Wide Human SNP
Array 6.0 platform passed quality control assessment. In stage 1,
comparison of the observed and expected distributions (quantile-
quantile plot: Figure S2) showed little evidence for an inflation
of the test statistics (genomic inflation factor l=1.01), there-
by excluding the possibility of significant hidden population
substructure, cryptic relatedness among subjects or differential
genotype calling between BRCA2 affected and BRCA2 unaffected
carriers. Multiple variants were found to be associated with breast
cancer risk (Figure S3): 3 SNPs had p,10
25 and 39 SNPs had
p,10
24. The most significant association (p~3:6|10{6) was
observed for FGFR2 rs2981582 (Table 1), a variant previously
shown to be associated with increased risk of BRCA2-related breast
cancer [13]. A positive association was also observed with
rs3803662 (Table 1), near TOX3, which has also been associated
with sporadic breast cancer risk [13].
Using the stage 1 data, we also performed a GSEA as
implemented in MAGENTA [14] to evaluate whether a
functionally-related set of genes relevant to BRCA2 function
(Table S1) was enriched for relative risk associations (see
Statistical Methods). The 59 genes selected are related to the
Fanconi anemia pathway [15] as well as other pathways reported
in the literature to regulate or interact with BRCA1/2 [16]. These
showed no enrichment of associations with the breast cancer risk
(p=0.56). In addition, eight of 125 known cancer susceptibility
alleles identified by previous GWAS of other cancers [17] were
associated with BRCA2 modification in the current study, a
number not greater than expected (Kolmogorv-Smirnov p=0.60)
by chance alone. Of the 113 most significantly associated SNPs
(p,10
23) in our study, three showed significant association
(p,0.05) with BRCA1-associated breast cancer risk in a
complimentary GWAS [18].
In the combined stage 1 and stage 2 results, four independent
SNPs (pairwise r2[0:80) were associated with increased risk of
breast cancer risk with p-values,10
24 (Table 1). Previously
identified breast cancer susceptibility loci [13,19,20] had the most
significant associations among BRCA2 mutation carriers (FGFR2:
per allele p{value~1:2|10{8 and TOX3: per allele
p{value~4:9|10{5). Novel loci, rs16917302 on chromosome
10 and rs311499 on chromosome 20, had HRs in stage 2 that were
in the same direction as those observed for stage 1 (Figure 1,
Table 1), but were smaller in magnitude (HR=0.67 (95%
CI:0.56–0.80) vs. 0.85 (95% CI: 0.70–1.04) for rs16917302;
HR=0.60 (95%CI:0.50–0.78) vs. 0.84 (95%CI: 0.67–1.06) for
rs311499) perhaps reflecting a ‘‘winner’s curse’’ effect’’ [21]. The
associations for these SNPs were not statistically significant in stage
2 (Table 1). In the combined stage 1 and stage 2 dataset, the C
allele of rs16917302 was associated with lower risk of breast cancer
(per allele HR=0.75, 95% CI 0.66–0.86; p~2:7|10{5; Table 1),
and the C allele of rs311499 was associated with a reduced risk
(per allele HR=0.72, 95% CI 0.61–0.85; p~7:9|10{5; Table 1).
A full list of stage 2 results can be found in Table S2. Using the
combined stage 1 and stage 2 data, there was no evidence that the
HR for SNP rs16917302 changes with age (p=0.63), but there
was some evidence that the per-allele HR for rs311499 may
increase with age (p=0.034).
Copy Number Variant Analysis
We also examined the association of both high-frequency CNPs
and low-frequency CNVs to case-control status using the stage 1
data. After performing standard quality control measures
including a minor allele frequency (MAF) threshold of 5%, we
identified 191 polymorphisms with reliable genotypes. No
associations were found between CNVs and the phenotype; there
was no inflation or deflation of the test statistic, and the best p-
value was 4|10{3. We similarly assessed less common CNPs, and
found neither the overall burden of events (or any subclass thereof,
such as large deletions overlapping genes) nor any specific locus
associated with breast cancer risk (Figure S4).
Author Summary
The risk of breast cancer associated with BRCA2 mutations
varies widely. To determine whether common genetic
variants modify the penetrance of BRCA2 mutations, we
conducted the first genome-wide association study of
breast cancer among women with BRCA2 mutations using
a two-stage approach. The major finding of the study is
that only those loci known to be associated with breast
cancer risk in the general population, including FGFR2
(rs2981575), modified BRCA2-associated risk in our high-
risk population. Two novel loci, on chromosomes 10 in
ZNF365 (rs16917302) and chromosome 20 (rs311499), were
shown to modify risk in BRCA2 mutation carriers, although
not at a genome-wide level of significance. However, the
ZNF365 locus has recently independently been associated
with breast cancer risk in sporadic tumors, highlighting the
potential significance of this zinc finger-containing gene in
breast cancer pathogenesis. Our results indicate that it is
unlikely that other common variants have a strong
modifying effect on BRCA2 penetrance.
BRCA2 GWAS
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Populations Analyzed
Because of the prior evidence of significant LD extent around
the 6174delT (c.5946delT) founder mutation in the Ashkenazi
Jewish population [22], we explored the potential excess sharing of
the genome compared to the BRCA2 region in both Ashkenazi
Jewish and non-Jewish European ancestries. Using GERMLINE
[23], shared segments of greater than 5 cM were computed based
on the imputed genotype dataset. In the BRCA2 region, we
observed a significant excess of sharing amongst both Ashkenazi
(n=304) and non-Jewish (n=1331) individuals compared to
samples from an autism study (n=808) suggesting common
founders for BRCA2 mutations. Examining sites across the genome
every 2.5 cM (excluding telomere and centromere regions), we
observed possible pairs share segments greater than 5 cM that on
average 0.005% (u=50.17, s.d=55.5, max=491) for non-Jewish
individuals and 0.12% (u=141.11, s.d=57.32, max=525) for
Ashkenazi Jewish individuals. Comparing cases and controls, we
did not observe a significant difference in number of pairs of
samples sharing segments greater than 5cM across the genome
excluding chromosome 13. That is, there was no evidence of
overall excess sharing across the genome other than for the BRCA2
locus within the Ashkenazi Jewish and non-Ashkenazi Jewish
populations in the study.
Discussion
In this GWAS of BRCA2 mutation carriers, the first in this high
risk population, we found previously identified breast cancer
susceptibility loci modified risk of BRCA2-associated breast cancer
with similar magnitude of association. Although FGFR2
(rs2981575) was the only locus to reach genome-wide statistical
significance, novel loci, rs16917302 and rs10509168 were each
associated with breast cancer risk.
rs16917302 is located on chromosome 10, in the zinc finger
protein 365 gene (ZNF365). A recent multistage GWAS of 15,992
sporadic breast cancer cases and 16,891 controls also observed an
inverse association (per allele OR=0.82, 95% CI 0.82–0.91,
p~5:1|10{15) between breast cancer risk and rs10509168, a
SNP 18kb from rs16917302 (pairwise r2~0:1) and located in
intron 4 of ZNF365 [24]. Of the 3,659 cases and 4,897 controls in
phase 1 of that study, imputation revealed that the locus identified
in our BRCA2 study, rs16917302, was significantly associated with
risk for breast cancer (p=0.02) (Easton DF, personal communi-
cation). The second novel SNP in the current study, rs311499, is
located on chromosome 20, within a region containing several
possible candidate genes including GMEB2, SRMS, PTK6,
STMN3, and TNFRSF6. The functional significance of both of
these regions with breast carcinogenesis is unknown; further
research is warranted.
There was some evidence that the HR associated with rs311499
may change with age. We also observed that the stage 1 HR for
this SNPs was larger in magnitude compared to the stage 2 HR,
consistent with a winner’s curse effect [21]. Since stage 1 of our
experiment included mostly BRCA2 mutation carriers diagnosed at
a young age, and stage 2 mutation carriers diagnosed an older age,
the ‘‘winner’s curse’’ and age-specific effects are confounded and
may be difficult to distinguish. Fitting the age-dependent HR
model for SNP rs311499 using the stage 2 data yielded no
significant variation in the HR by age (p=0.47), but the sample
size for this analysis was relatively small. Future larger studies
should aim to clarify this.
Mutations in known genes (BRCA1, BRCA2, TP53, CHEK2,
PTEN, and ATM) explain only 20–25% of the familial clustering of
breast cancer; the residual familial clustering may be explained by
the existence of multiple common, low-penetrance alleles
(‘polygenes’) [25]. Perhaps because the majority of BRCA2-
associated breast tumors are estrogen receptor (ER)-positive, as
are the majority of non-hereditary breast cancers [26], risk alleles
for sporadic breast cancer are more likely to be modifiers of risk of
BRCA2-associated hereditary breast cancer. Of the seven GWAS-
identified breast cancer-associated SNPs examined in a BRCA2
background [13,19,20], SNPS in FGFR2 (rs2981575), TOX3
(rs3803662), MAP3K1 (rs889312), and LSP1 (rs3817198) have
been shown to modify BRCA2 penetrance, in contrast with BRCA1
tumors, in which only two of these same SNPs (based on a 2
degrees of freedom model) modified risk of these largely ER-
negative tumors [26]. As previously noted [13,20], the stage 1 HRs
among BRCA2 mutation carriers, reported here, were nearly
identical to odds ratio estimates observed in sporadic breast cancer
studies, consistent with a simple multiplicative interaction between
the BRCA2 mutant alleles and the common susceptibility SNPs. If
Table 1. Estimates of breast cancer association for loci (two confirmatory loci at FGFR2 and TOX3, and two novel loci with stage 1
and 2 combined of p,10
24) among BRCA2 mutation carriers in a two-staged genome-wide association study.
Gene SNP Chr. Stage 1 Stage 2 Stage 1 and 2 Combined
N (Controls/
Cases) p-value
2
HR (95%
CI)
1
N (Controls/
Cases)
HR (95%
CI)
1 p-value
2
N (Controls/
Cases) MAF
HR (95%
CI)
1 p-value
2
FGFR2 rs2981575 10 794/892 6.0610
26 1.30
(1.16–1.45)
1,222/1,263 1.26
(1.11–1.43)
4.4610
24 2,016/2,155 0.42 1.28
(1.18–1.39)
1.2610
28
TOX3 rs3803662 16 804/899 5.8610
23 1.19
(1.05–1.34)
1,222/1,263 1.22
(1.07–1.39)
2.8610
23 2,026/2,162 0.29 1.20
(1.10–1.31)
4.9610
25
ZNF365 rs16917302 10 804/898 1.8610
25 0.67
(0.56–0.80)
1,222/1,264 0.85
(0.70–1.04)
0.14 2,026/2,162 0.11 0.75
(0.66–0.86)
3.8610
25
GMEB2,
Etc.
3
rs311499 20 792/882 3.5610
25 0.60
(0.47–0.78)
1,209/1,255 0.84
(0.67–1.06)
0.13 2,001/2,137 0.07 0.72
(0.61–0.85)
6.6610
25
1p-value was calculated based on the 1-degree of freedom score test statistic stratified by country of study and 6174delT (c.5946delT) mutation status, and modified to
allow for the non-independence among related individuals.
2Per allele hazard ratios (HR) (i.e., multiplicative model) were estimated on the log scale, assuming independence of age, using the retrospective likelihood. All analyses
were stratified by country of residence and 6174delT (c.5946delT) mutation status, and used calendar-year- and cohort-specific breast cancer incidence rates for BRCA2.
The combined stage 1 and stage 2 analyses were also stratified by stage.
3The region also includes other possible genes including SRMS, PTK6, STMN3, and TNFRSF6 among others.
doi:10.1371/journal.pgen.1001183.t001
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PLoS Genetics | www.plosgenetics.org 4 October 2010 | Volume 6 | Issue 10 | e1001183Figure 1. Association signals, genetic structure, and linkage disequilibrium of the novel modifier loci of BRCA2 penetrance in the
regions surrounding rs1691730 on chromosome 10 and rs311499 on chromosome 20. The color of the dots indicates linkage
disequilibrium (LD; based on r2 values) in the CEU population (as per scale). Triangle plots below represent LD from actual data of BRCA2 carries in the
study.
doi:10.1371/journal.pgen.1001183.g001
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explain about 1.7% of the variance in breast cancer risk among
BRCA2 mutation carriers. Taken together, the combined effects of
all the common and putative risk modifiers in this study only
account for ,4% of the variance of BRCA2 mutations, compared
with 1.1% for the single RAD51 135 G.C variant, which is rare
and biologically-linked to BRCA2 function, as shown by candidate
gene studies [9]. Thus, the common alleles that modify risk in
BRCA1 and BRCA2 backgrounds appear to have comparable
associated risks in sporadic ER-positive and ER-negative tumors,
respectively [18]. While individual SNPs are unlikely to be used to
guide radiographic screening and risk-reducing surgical strategies,
the combined effect of these SNPs may ultimately be used for the
tailor management of subsets of BRCA mutation carriers [5].
While we took great efforts to collect all of the possible known
BRCA2 mutation carriers, there were insufficient numbers to
stratify by race and BRCA2 mutations with the exception of
BRCA2*6174delT mutations. Due to the small numbers of women
of non-European ancestry who have participated in the individual
studies represented here, the current analysis was based only on
women who had genetic backgrounds consistent with HapMap
CEU samples. While we expect that SNPs identified among
women of European ancestry might also be applicable to women
of other genetic backgrounds, additional research in these
populations will be needed. Similarly, the observed associations
represented across all types of mutations, and specifically a
weighted average of BRCA2*6174delT and non-delT mutations. It
is possible that the observed associations may only modify the
penetrance of specific BRCA2 mutations due to differential effects
on function or differences in genetic background. Our analysis was
stratified on the basis of the most common BRCA2 mutation,
BRCA2*6174delT, which is prevalent in individuals with an
Ashkenazi Jewish ancestry. Large numbers of mutation carriers
will be necessary to calculate mutation-specific estimates. In
addition, there was a drop-out of SNPs in the two phases of this
study. While we were able to achieve a representative coverage of
the genome, it is also possible that additional studies using denser
arrays may provide further information.
As expected, we observed associations with some of the major
common genetic variants seen in genome-wide scans of breast
cancer in a non-BRCA1/2 mutation background. However, we
found no evidence for loci with stronger effects than FGFR2.
Although we observed an association with a novel locus at ZNF365
that appears also to be a risk factor for sporadic breast cancer,
overall, our results suggest that there are no common variants with
major effects (i.e., OR.2.0) that are specific in BRCA2 carriers.
Similarly, in a recent report of SNPs from sporadic breast cancer
GWAS genotyped in a restricted set of BRCA1/2 carriers [27], loci
in LOC134997 (rs9393597: per allele HR=1.55, 95% CI 1.25–
1.92, p~6:0|10{5) and FBXL7 (rs12652447: HR=1.37, 95%
CI 1.16–1.62, p~1:7|10{4) were associated with BRCA2 breast
cancer risk with p-values weaker than FGFR2 reported here (per
allele p{value~1:2|10{8), although the magnitudes of the
associations were slightly stronger than FGFR2 (HR=1.28).
Although these SNPs were not in our genotyped panel of SNPs
at stage 1, imputation results indicate that SNP rs9393597 has a p-
value of 0.008 and SNP rs12652447 a p-value of 0.04 for
association with breast cancer risk for the BRCA2 mutation carriers
in our stage1. However, there is substantial overlap between our
study and the study of Wang et al. [27].
Replication in larger datasets will be necessary to precisely
estimate the magnitude of the associations of suspected loci
identified from our study, candidate gene analysis [10–12], and
other selection approaches [27]. It is of interest, however, that
when utilizing an agnostic approach in BRCA2 mutation carriers
in this study, the major determinants of risk variation in mutation
carriers are those that also modify risk in subsets of sporadic,
BRCA1/2 wild type, breast cancer. However, it remains possible
that unique variants with smaller effects, or rarer variants (not
evaluated in this experiment), may be specific modifiers of breast
cancer risk in BRCA2 carriers. Their detection would require study
populations much larger than the current analysis, which is
presently the largest such cohort assembled.
Materials and Methods
Study Subjects
Ethics statement. All carriers were recruited to studies
(Table 2) at the host institutions under IRB-approved protocols.
Selection of affected individuals and controls. A total of
6,272 BRCA2 carriers from 39 studies (Table 2) and 14 countries
contributed DNA samples for this project. With the exception of
NICC, all studies are members of the Consortium of Investigators
of Modifiers of BRCA1/2 (CIMBA) [28]. Recruitment of carriers
were conducted predominantly through cancer genetics clinics,
and enrolled through national or regional efforts. Other studies
were recruited through population-based or community-based
ascertainments. All subjects provided written informed consent.
Eligible female carriers were aged 18 years or older, were self-
reported ‘white’, and had mutations in BRCA2. Data were
available on age at study recruitment, age at cancer diagnosis,
age of bilateral prophylactic mastectomy, BRCA1/2 mutation
description, and self-reported ethnicity. Only a limited number of
cases had detailed information on tumor characteristics (e.g.,
estrogen and progesterone receptor status); therefore, subtype
analyses were not performed at this stage.
Genotyping and Quality Control
Stage 1 Affymetrix genotyping. All eligible DNA samples
provided by participating centers were subjected to a rigorous
quality control assessment, including measures of overall DNA
quality and quantity. A total of 1,156 young (#50 years) affected
women and 1,038 unaffected women with high quality DNA
samples were selected (Table 2). For time efficiency, stage 1
genotyping occurred in two phases: phase 1 included 421 cases
and 404 controls and phase 2 included 735 cases and 634 controls.
Prior to the genome-wide scan, we genotyped five SNPs
previously genotyped by the CIMBA study centers as a pre-filter
for sample identification. Thirty-one samples (Figure S1) were
discordant in the two genotyping rounds and were excluded from
further analysis.
The genotyping for the stage 1 GWAS was performed on 2,163
eligible carriers using the Affymetrix 6.0 GeneChip array that
included 906,622 SNPs (Figure S1). To further monitor the identity
of the DNAsamples, a fingerprinting panel of14 SNPs with a minor
allele frequency .10% in HapMap European individuals were
genotyped on all samples, using Sequenom iPLEX, before and after
Affymetrixgenotyping.TheAMGgenderassaywasused forgender
assessment. As an additional quality control measure, cases and
controls were interleafed on each plate to eliminate technical bias.
Each plate also included one HapMap CEU DNA sample.
The DNA samples and genotyping calls for both phases of stage
1 were filtered through a series of data quality control parameters
using the Birdseed module of the Birdsuite software developed at
Broad Institute [29]. Among the 2,163 samples genotyped in the
stage 1 GWAS, 253 failed to hybridize to the chip due to poor
DNA quality and were excluded (Figure S1). Fifty-five samples
were dropped with call rates ,95%. Three samples were
BRCA2 GWAS
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Stage 1 Stage 2
Affected (n=1,156)
Unaffected
(n=1,038) Affected (n=1,524) Unaffected (n=1,508)
Factor N % N % N % N %
Age at Censoring
,40 763 66.7 11 1.1 368 23.7 1007 66.0
40–44 308 26.9 230 22.2 225 14.5 119 7.8
45–49 72 6.3 232 22.4 334 21.5 131 8.6
50–54 1 0.1 176 17.0 286 18.4 90 5.9
55–59 0 0.0 138 13.3 164 10.5 73 4.8
60+ 0 0.0 248 24.0 178 11.4 105 6.9
Self-reported Ethnicity
Unknown 125 10.9 80 7.7 329 21.2 293 19.2
Caucasian 873 76.3 723 69.9 1037 66.7 1036 67.9
Ashkenazi Jewish 146 12.8 232 22.4 189 12.2 196 12.9
DelT Mutation
Carrier 161 14.1 271 26.2 233 15.0 239 15.7
Non-carrier 983 85.9 764 73.8 1322 85.0 1286 84.3
Country of Study
Australia 109 9.5 82 7.9 149 9.6 180 11.8
Canada 98 8.6 172 16.6 55 3.5 82 5.4
Denmark 0 0.0 0 0.0 43 2.8 32 2.1
France 52 4.5 25 2.4 172 11.1 50 3.3
Finland 27 2.4 27 2.6 32 2.1 27 1.8
Germany 68 5.9 31 3.0 116 7.5 54 3.5
Iceland 25 2.2 9 0.9 81 5.2 6 0.4
Israel 49 4.3 87 8.4 77 5.0 86 5.6
Italy 110 9.6 44 4.3 98 6.3 62 4.1
Spain 107 9.4 71 6.9 99 6.4 136 8.9
Sweden 13 1.1 13 1.3 11 0.7 15 1.0
The Netherlands 15 1.3 26 2.5 117 7.5 201 13.2
United Kingdom 181 15.8 179 17.3 125 8.0 168 11.0
USA 290 25.4 290 28.0 380 24.3 426 27.9
Study
BCFR-Australia 19 1.7 5 0.5 12 0.8 10 0.7
BCFR-NCCC 12 1.0 1 0.1 5 0.3 2 0.1
BCFR-Ontario 29 2.5 28 2.7 16 1.0 17 1.1
BCFR-UT 18 1.6 18 1.7 11 0.7 47 3.1
BCFR-FCCC 2 0.2 1 0.1 14 0.9 10 0.7
BCFR-NY 4 0.3 5 0.5 26 1.7 16 1.0
BIDMC 10 0.9 20 1.9 7 0.5 12 0.8
CBCS 0 0.0 0 0.0 43 2.8 32 2.1
CGB_NCI 7 0.6 15 1.4 14 0.9 43 2.8
CNIO 49 4.3 33 3.2 40 2.5 56 3.7
COH 30 2.6 13 1.3 21 1.4 16 1.0
DFCI 14 1.2 22 2.1 10 0.6 24 1.6
DKFZ 7 0.6 5 0.5 8 0.5 7 0.5
EMBRACE 178 15.6 173 16.7 123 7.9 161 10.6
FCCC 14 1.2 10 1.0 12 0.8 9 0.6
GC-HBOC 61 5.3 26 2.5 108 6.9 47 3.1
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and 4 were male; all were dropped from analyses.
SNPs were also filtered using Birdseed and were removed if
monomorphic or .10% missing (n=38,962), genotype call rates
,95% (n=50,810), minor allele frequencies ,1% (n=104,792),
departures from Hardy-Weinberg Equilibrium (p,10
26;
n=1,090), differential missingness with respect to phenotype
(p,10
23; n=275), and differential missingness with respect to
nearby SNPs (p,10
210; n=22,065). A total of 6,212 SNPs had
different missingness patterns in phase 1 compared to phase 2, and
were excluded. Since we found that significant missingness
correlated to SNPs mapping to longer fragments of Affymetrix
6.0 digestion products, we also removed the SNPs on fragments
longer than 1000bp (n=85,990).
With the remaining 1,805 carriers and 596,426 SNPs, an
iterative process proceeded to drop all individuals with low call
rates (,95%), high autosomal heterozygosity rates (false discovery
rate ,0.1%), and high identity by descent scores ($0.95) and to
drop all SNPs with minor allele frequencies ,1% and SNP call
rates ,95% until the final run contained individuals above the
individual and SNP filter thresholds (n=1,747 samples and
592,566 SNPs). A more stringent HWE filter (p,10
27) was then
applied and 403 additional SNPs were dropped. Nine individuals
with missing mutation descriptions were removed.
Finally, principal components analysis was used to identify the
ethnic outliers (Figure S5). A total of 1,743 BRCA2 mutation
carriers and the HapMap3 data for 210 individuals of European
(CEU), Han Chinese (CHB), and Yoruba (YRI) African descent
were available for multidimensional scaling using the genomic
kinship matrix estimated using a set of 53,641 autosomal and
uncorrelated SNPs. A cut-off of .11% was used to exclude
samples with non-CEU ancestry (n=35). Genotype-phenotype
association analyses were based on 1,703 (899 young affected and
804 unaffected) BRCA2 mutation carriers and 592,163 SNPs,
covering 85% of the common HapMap 3 SNPs (imputed with
r2]0:8 (see below), including 64% of the markers that were
removed in the QC process).
Where directly genotyped data were not available, probabilities
were imputed with Beagle.3.0.2 (using the default parameters)
using CEU+TSI samples on HapMap3 release2 B36 as the
reference panel (410 chromosomes, 1.4 M SNPs).
Stage 2 Sequenom iPLEX genotyping. The primary SNP
selection strategy was based on the results of the kinship-adjusted
score test of 592,163 GWAS genotyped SNPs. From stage 1, a
total of 79 top independent regions (pƒ1:5|10{4) with pairwise
r
2 values,0.80 were selected for genotyping in stage 2 (Figure S6).
For the top 10 SNPs if available, an additional correlated SNP
(pairwise r2values]0:8; n=5) was selected to serve as genotyping
Stage 1 Stage 2
Affected (n=1,156)
Unaffected
(n=1,038) Affected (n=1,524) Unaffected (n=1,508)
Factor N % N % N % N %
GEMO 52 4.5 25 2.4 172 11.0 50 3.3
GOG 64 5.6 51 4.9 57 3.7 91 6.0
HCSC 27 2.4 20 1.9 34 2.2 35 2.3
HEBON 10 0.9 17 1.6 103 6.6 172 11.3
HEBCS 27 2.4 27 2.6 32 2.1 27 1.8
ICO 31 2.7 18 1.7 25 1.6 45 3.0
ILUH 26 2.3 9 0.9 81 5.2 6 0.4
IOVHBOCS 19 1.7 7 0.7 44 2.8 20 1.3
kConFab 88 7.6 77 7.3 137 8.7 168 11.0
LUMC 5 0.4 9 0.9 14 0.9 29 1.9
MAGIC-UC 2 0.2 2 0.2 0 0.0 3 0.2
MAGIC-UCI 6 0.5 9 0.9 21 1.4 22 1.4
MAYO 5 0.4 14 1.4 51 3.3 24 1.6
MBCSG 91 8.0 37 3.6 54 3.5 42 2.8
MSKCC 51 4.5 61 5.9 52 3.3 47 3.1
NICC 28 2.4 60 5.8 46 3.0 67 4.4
OCGN 62 5.4 60 5.8 35 2.2 36 2.4
OSU CCG 11 1.0 8 0.8 9 0.6 8 0.5
SMC 21 1.8 27 2.6 31 2.0 19 1.2
SWE-BRCA 13 1.1 13 1.3 11 0.7 15 1.0
UCSF 10 0.9 6 0.6 12 0.8 8 0.5
UKGRFOCR 2 0.2 6 0.6 2 0.1 7 0.5
UPENN 33 2.9 13 1.3 58 3.7 46 3.0
WCRI 6 0.5 84 8.1 4 0.3 29 1.9
doi:10.1371/journal.pgen.1001183.t002
Table 2. Cont.
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two alternate strategies. First, we added the 14 (as well as FGFR2
counted in the top 10 SNPs above) confirmed breast cancer SNPs
from prior independent GWAS of sporadic breast cancer. Second,
we also selected the 15 top independent regions (pairwise
r2[0:50) based on the ranking of the p-values from a logistic
regression analysis of 1.5 million imputed SNPs. In total for stage 2
replication phase, we selected 113 SNPs and 1,524 breast cancer
carriers and 1,508 control carriers (Table 2) for genotyping using
the Sequenom iPLEX platform.
Samples were excluded for call rates #95% (n=476),
duplication in stage 2 (identity by state (IBS),1.0; n=43),
duplication in stage 1 and 2 (IBS; n=25), lack of complete
phenotype data (n=1), and insufficient country-specific numbers
(n=1; Figure S6). A total of 100 SNPs were successfully
multiplexed into three pools; the remaining 13 SNPs were not
genotyped. Genotyping QC filters excluded 15 SNPs due to call
rates #90% (n=14) and MAF,1% (n=1). In summary, the final
association analyses in stage 2 were based on 2,486 carriers (1,264
affected and 1,222 unaffected carriers) and 85 SNPs.
Statistical Methods
Defining time at risk. Carriers were censored at the first
breast or ovarian cancer or bilateral prophylactic mastectomy,
whichever occurred first. Carriers who developed any cancer were
censored at time of bilateral prophylactic mastectomy if it
occurred more than a year prior to the cancer diagnosis (to
avoid censoring at bilateral mastectomies related to diagnosis in
which rounded ages were used). The remaining carriers were
censored at the age of last observation. This was defined either by
the age/date at interview or age at follow-up depending on the
information provided by the participating center. Carriers
censored at diagnosis of breast cancer were considered cases in
the analysis. Mutation carriers censored at ovarian cancer
diagnosis were considered unaffected. Carriers with a censoring/
last follow-up age older than age 80 were censored at age 80
because there are no reliable cancer incidence rates for BRCA1/2
carriers beyond age 80.
Genotype–phenotype associations. Analyses, based on
1,703 BRCA2 mutation carriers and 592,163 SNPs, were
performed within a survival analysis framework. Since the
mutation carriers were not selected at random with respect to
their disease status, standard methods of survival (e.g., Cox
regression) may lead to biased estimates of relative risk [30].
Therefore, analyses were conducted by modeling the retrospective
likelihood of the observed genotypes conditional on the disease
phenotypes. The associations between genotype and breast cancer
risk at both stages were assessed using the 1-degree of freedom
score test statistic based on this retrospective likelihood, as
previously described [9,18]. All models were stratified by
country of study and 6174delT (c.5946delT) mutation status, the
most common BRCA2 mutation in this study and a marker of the
Ashkenazi Jewish population among Ashkenazi Jewish women
[31–33]. Since the linkage disequilibrium structure among
Ashkenazi Jewish people may differ from other mutation carriers
[34], stratifying by the *6174delT provides additional control for
population stratification. To allow for the non-independence
among related individuals, an adjusted version of the score test was
used in which the variance of the score was derived by taking into
account the correlation between the genotypes [35,36]. Analyses
were performed in R using the GenABEL libraries [37] and
custom written software.
To estimate the magnitude of the associations, the effect of each
SNP was modelled either as a per allele hazard ratio (HR) (i.e.,
multiplicative model) or as separate HRs for heterozygotes and
homozygotes, and these were estimated on the log scale. The HRs
were assumed to be independent of age (i.e. we used a Cox
proportional-hazards model). For the most significant novel
associations this assumption was verified by adding a genotype-
by-age interaction term to the model to fit models in which the
HR changed with age. The retrospective likelihood was imple-
mented in the pedigree-analysis software MENDEL [38] as
previously described [9]. All analyses were stratified by country of
residence and 6174delT (c.5946delT) mutation status, and used
calendar-year- and cohort-specific breast cancer incidence rates
for BRCA2 [25]. The combined stage 1 and stage 2 analyses were
also stratified by stage. Parameter estimates were obtained by
maximising the retrospective likelihood. To allow for the non-
independence among related mutation carriers, we used a robust
variance estimation approach in order to obtain standard errors
for the parameters [39,40]. Related individuals were identified
through a unique family identifier.
Copy number variant analysis. We also examined the
association of both high-frequency and low-frequency copy
number variants (CNV) to the age of diagnosis of breast cancer
as a dichotomous trait using the stage 1 data [29]. We called
known, common variants (copy number polymorphisms, CNPs)
with Canary [29]. CNP alleles lower than 1% in frequency were
removed, to maximize the number of the CNPs that were bi-allelic
instead of multi-alleleic. CNPs were removed that had for call rate
,95%, differential missingness by genotype (p,10
23), or
departure from Hardy-Weinberg proportions (p,10
23). Post-
QC, we had 191 high-quality genotyped polymorphisms. We used
PLINK to assess association using logistic regression and the same
ancestry covariates of no interest as with SNPs. We similarly
assessed less common CNVs discovered by Birdseye [29] for
association with age at diagnosis using PLINK [41]. Finally, we
also looked specifically at CNVs overlapping the BRCA2 gene itself
using LOD scores and Birdseye.
Haplotype sharing analysis. We looked for evidence of
excess sharing across the genome and the BRCA2 region. Using
GERMLINE [23], shared segments of greater than 5 cM were
computed based on the imputed genotype dataset among both
Ashkenazi (n=304) and non-Jewish (n=1,331) samples compared
to samples from an autism study (n=808) (Figure S3). Examining
sites across the genome every 2.5 cM (excluding telomere and
centromere regions), we computed the mean of the proportion,
standard deviation, and the maximum values for non-Jewish and
Ashkenazi women, respectively.
Gene Set Enrichment Analysis. We tested whether 59
genes known to regulate or interact with BRCA2 [16] (Table S1)
were enriched for associations with age of onset of breast cancer in
BRCA2 mutation carriers, using a new implementation of Gene
Set Enrichment Analysis (GSEA) called Meta-Analysis Gene-Set
Enrichment of variaNT Associations (MAGENTA) [14]. The 59
genes were compiled using a Pubmed abstract mining software,
Chilibot [42], and were selected if they were related to the Fanconi
anemia pathway [15] as well as others reported from literature to
regulate or interact with BRCA1/2 [43]. An association p-value
was calculated for each gene in the genome, defined as the most-
significant association p-value of all genotyped SNPs that lie within
110 kb upstream and 40 kb downstream to the gene’s most
extreme transcript boundaries, followed by correction for gene
score confounders (gene size, number of SNPs per gene and
linkage disequilibrium related properties). SNP association p-
values were taken from the stage 1 GWAS. To compute a GSEA
p-value for the BRCA gene set, the fraction of genes with an
association p-value more significant than the 95 percentile of all
BRCA2 GWAS
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generated by randomly sampling gene-sets of identical size from
the genome 10,000 times. Of the 59 BRCA interactors, two genes
were assigned the same most significant SNP due to physical
proximity in the genome. To prevent potential over-estimation of
gene set enrichment due to physical clustering of genes in a gene
set, we retained only one gene of each subset of genes assigned the
same best SNP (the gene with the most significant gene p-value) for
the analysis of both the real and permuted gene sets.
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Figure S1 Data filtering of stage 1 BRCA2 GWAS.
Found at: doi:10.1371/journal.pgen.1001183.s001 (0.57 MB
TIF)
Figure S2 Quantile-quantile plot comparing expected distribu-
tion of chi-square values and observed chi-square values from a
genome-wide scan of breast cancer cases and unaffected BRCA2
carriers.
Found at: doi:10.1371/journal.pgen.1001183.s002 (0.31 MB
TIF)
Figure S3 Manhattan plot of p-values by chromosomal position
from a genome-wide scan of breast cancer cases and unaffected
BRCA2 carriers [Visualized using SVS7 (Goldenhelix)].
Found at: doi:10.1371/journal.pgen.1001183.s003 (0.51 MB
TIF)
Figure S4 Quantile-quantile plot comparing expected distribu-
tion of p-values and observed p-values of association of common
copy number polymorphisms (CNPs) from a genome-wide scan of
breast cancer cases and unaffected BRCA2 carriers.
Found at: doi:10.1371/journal.pgen.1001183.s004 (0.32 MB TIF)
Figure S5 Principal components analysis, including all eligible
(after filtering) BRCA2 stage 1 samples and HapMap samples.
Found at: doi:10.1371/journal.pgen.1001183.s005 (2.39 MB
TIF)
Figure S6 Data filtering of stage 2 BRCA2 GWAS.
Found at: doi:10.1371/journal.pgen.1001183.s006 (0.35 MB
TIF)
Table S1 List of 59 BRCA interactors or regulators and their
gene association p-values to breast cancer age of onset in BRCA2
mutation carriers.
Found at: doi:10.1371/journal.pgen.1001183.s007 (0.13 MB
DOC)
Table S2 Ranked results for the 85 SNPs successfully genotyped
in stage 2, BRCA2 GWAS.
Found at: doi:10.1371/journal.pgen.1001183.s008 (0.13 MB
DOC)
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